US 12,422,439 B2
Use of sCD14 or its fragments or derivatives for risk stratification, diagnosis and prognosis
Eberhard Spanuth, Dossenheim (DE)
Assigned to PHC CORPORATION, Ehime (JP)
Filed by PHC Corporation, Ehime (JP)
Filed on Apr. 15, 2019, as Appl. No. 16/384,170.
Application 16/384,170 is a continuation of application No. 14/655,803, abandoned, previously published as PCT/EP2013/078062, filed on Dec. 27, 2013.
Claims priority of application No. 12199701 (EP), filed on Dec. 28, 2012.
Prior Publication US 2019/0257841 A1, Aug. 22, 2019
Int. Cl. G01N 33/68 (2006.01)
CPC G01N 33/6893 (2013.01) [G01N 33/6872 (2013.01); G01N 2333/70596 (2013.01); G01N 2800/32 (2013.01); G01N 2800/323 (2013.01); G01N 2800/324 (2013.01); G01N 2800/325 (2013.01); G01N 2800/50 (2013.01); G01N 2800/52 (2013.01); G01N 2800/56 (2013.01)] 4 Claims
 
1. A method of diagnosing and treating a cardiovascular disease or condition in a patient, said method comprising:
a. obtaining a blood, plasma, or serum sample from a human patient;
b. detecting sCD14-ST present in the blood, plasma, or serum sample, or having sCD14-ST detected in the blood, plasma, or serum sample;
c. diagnosing the patient with a cardiovascular disease or condition when the presence of sCD14-ST in the blood, plasma, or serum sample is detected; and
d. administering an appropriate treatment to the diagnosed patient, wherein an amount of sCD14-ST in the diagnosed patient to be administered is 345 pg/ml or higher, and wherein the appropriate treatment is selected from the group consisting of antibiotics, probiotics, and lactulose;
wherein the patient shows symptoms of one or more cardiovascular diseases or conditions selected from the group consisting of chronic heart failure and angina pectoris; and
wherein the sCD14-ST has an apparent molecular weight of 13±2 kDa when electrophoresed under non-reducing conditions.